Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;16(4):208-221.
doi: 10.1038/s41584-020-0386-4. Epub 2020 Feb 25.

Raynaud phenomenon and digital ulcers in systemic sclerosis

Affiliations
Review

Raynaud phenomenon and digital ulcers in systemic sclerosis

Michael Hughes et al. Nat Rev Rheumatol. 2020 Apr.

Erratum in

Abstract

Raynaud phenomenon is a symptom complex caused by impaired digital perfusion and can occur as a primary phenomenon or secondary to a wide range of underlying causes. Raynaud phenomenon occurs in virtually all patients with systemic sclerosis (SSc) and is often the earliest clinical manifestation to occur. Careful assessment is required in patients with Raynaud phenomenon to avoid missing secondary causes such as SSc. Digital ulcers are a painful and disabling visible manifestation of digital vascular injury in patients with SSc. Progress has been made in the classification and assessment of digital ulcers and in understanding ulcer pathogenesis, and there are a wide range of treatments available to both prevent and heal digital ulcers, some of which are also used in Raynaud phenomenon management. In this Review, the assessment of patients with Raynaud phenomenon is discussed, including 'red flags' that are suggestive of SSc. The pathogenesis, classification and assessment of SSc-associated digital ulcers are also covered, alongside an overview of management approaches for SSc-associated Raynaud phenomenon and digital ulcers. Finally, unmet needs are discussed and the concept of a unified vascular phenotype in which therapies that affect the vasculature to support disease modification strategies is introduced.

PubMed Disclaimer

References

    1. Katsumoto, T. R. & Whitfield, M. L. The pathogenesis of systemic sclerosis. Annu. Rev. Pathol. 6, 509–537 (2011). - DOI
    1. Denton, C. P. & Khanna, D. K. Systemic sclerosis. Lancet 390, 1685–1699 (2017). - DOI - PubMed - PMC
    1. Meier, F. M. P. et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann. Rheum. Dis. 71, 1355–1360 (2012). - DOI
    1. Merkel, P. A. et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 46, 2410–2420 (2002). - DOI - PubMed - PMC
    1. LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988). - PubMed

LinkOut - more resources